Anti fibrin monoclonal antibody 3B6/22 Tc 99m

Drug Profile

Anti fibrin monoclonal antibody 3B6/22 Tc 99m

Alternative Names: Tc 99m 3B6/22; Tc 99m anti-fibrin monoclonal antibody 3B6/22; ThromboView

Latest Information Update: 07 Dec 2015

Price : $50

At a glance

  • Originator Agenix
  • Class Imaging agents; Monoclonal antibodies; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Deep vein thrombosis; Pulmonary embolism

Highest Development Phases

  • Discontinued Deep vein thrombosis; Pulmonary embolism

Most Recent Events

  • 07 Dec 2015 Discontinued - Phase-II for Pulmonary embolism (Diagnosis) in USA and Canada (IV)
  • 07 Dec 2015 Discontinued - Phase-II for Deep vein thrombosis (Diagnosis) in USA and Canada (IV)
  • 07 Dec 2015 Discontinued - Phase-I for Pulmonary embolism (Diagnosis) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top